ONCOLOGY INSTITUTE INC/THE (TOI) Fundamental Analysis & Valuation

NASDAQ:TOI • US68236X1000

Current stock price

3.54 USD
-0.06 (-1.67%)
At close:
3.55 USD
+0.01 (+0.28%)
After Hours:

This TOI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. TOI Profitability Analysis

1.1 Basic Checks

  • In the past year TOI has reported negative net income.
  • In the past year TOI has reported a negative cash flow from operations.
  • TOI had negative earnings in 4 of the past 5 years.
  • In the past 5 years TOI always reported negative operating cash flow.
TOI Yearly Net Income VS EBIT VS OCF VS FCFTOI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -33.41%, TOI is not doing good in the industry: 86.14% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -33.41%
ROE N/A
ROIC N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
TOI Yearly ROA, ROE, ROICTOI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • The Gross Margin of TOI (14.82%) is worse than 63.37% of its industry peers.
  • TOI's Gross Margin has declined in the last couple of years.
  • TOI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
TOI Yearly Profit, Operating, Gross MarginsTOI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TOI Health Analysis

2.1 Basic Checks

  • TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TOI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TOI Yearly Shares OutstandingTOI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TOI Yearly Total Debt VS Total AssetsTOI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of 1.27, we must say that TOI is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.27, TOI is not doing good in the industry: 62.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.27
ROIC/WACCN/A
WACC8.16%
TOI Yearly LT Debt VS Equity VS FCFTOI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.68 indicates that TOI should not have too much problems paying its short term obligations.
  • TOI has a Current ratio of 1.68. This is in the better half of the industry: TOI outperforms 67.33% of its industry peers.
  • TOI has a Quick Ratio of 1.39. This is a normal value and indicates that TOI is financially healthy and should not expect problems in meeting its short term obligations.
  • TOI has a Quick ratio (1.39) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.68
Quick Ratio 1.39
TOI Yearly Current Assets VS Current LiabilitesTOI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TOI Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41.58%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.82% on average over the next years. This is a very strong growth
  • TOI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.58% yearly.
EPS Next Y42.22%
EPS Next 2Y35.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.42%
Revenue Next 2Y27.58%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

TOI Yearly Revenue VS EstimatesTOI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
TOI Yearly EPS VS EstimatesTOI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

1

4. TOI Valuation Analysis

4.1 Price/Earnings Ratio

  • TOI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TOI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOI Price Earnings VS Forward Price EarningsTOI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOI Per share dataTOI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TOI's earnings are expected to grow with 35.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.82%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TOI Dividend Analysis

5.1 Amount

  • TOI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TOI Fundamentals: All Metrics, Ratios and Statistics

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (3/19/2026, 8:00:01 PM)

After market: 3.55 +0.01 (+0.28%)

3.54

-0.06 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-12
Earnings (Next)05-12
Inst Owners44.92%
Inst Owner Change12.36%
Ins Owners8.83%
Ins Owner Change-14.1%
Market Cap349.89M
Revenue(TTM)N/A
Net Income(TTM)-54.66M
Analysts82.5
Price Target6.63 (87.29%)
Short Float %10.8%
Short Ratio4.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.28%
Min EPS beat(2)-22.31%
Max EPS beat(2)-14.24%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.88%
Min Revenue beat(2)3.5%
Max Revenue beat(2)10.26%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.39%
EPS NY rev (1m)-2.17%
EPS NY rev (3m)-5.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.76
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS4.66
BVpS-0.12
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.82%
FCFM N/A
ROA(3y)-21.03%
ROA(5y)-18.04%
ROE(3y)-531.94%
ROE(5y)-331.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.94%
GM growth 5Y-6.53%
F-Score4
Asset Turnover2.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.49%
Cap/Sales 0.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.68
Quick Ratio 1.39
Altman-Z 1.27
F-Score4
WACC8.16%
ROIC/WACCN/A
Cap/Depr(3y)87.81%
Cap/Depr(5y)78.43%
Cap/Sales(3y)1.52%
Cap/Sales(5y)1.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y42.22%
EPS Next 2Y35.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41.58%
Revenue Next Year29.42%
Revenue Next 2Y27.58%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.83%
EBIT Next 3Y47.2%
EBIT Next 5YN/A
FCF growth 1Y47.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.09%
OCF growth 3YN/A
OCF growth 5YN/A

ONCOLOGY INSTITUTE INC/THE / TOI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a fundamental rating of 1 / 10 to TOI.


Can you provide the valuation status for ONCOLOGY INSTITUTE INC/THE?

ChartMill assigns a valuation rating of 1 / 10 to ONCOLOGY INSTITUTE INC/THE (TOI). This can be considered as Overvalued.


How profitable is ONCOLOGY INSTITUTE INC/THE (TOI) stock?

ONCOLOGY INSTITUTE INC/THE (TOI) has a profitability rating of 0 / 10.


Can you provide the financial health for TOI stock?

The financial health rating of ONCOLOGY INSTITUTE INC/THE (TOI) is 2 / 10.


Can you provide the expected EPS growth for TOI stock?

The Earnings per Share (EPS) of ONCOLOGY INSTITUTE INC/THE (TOI) is expected to grow by 42.22% in the next year.